Wordt geladen...
Limited-stage DLBCL: it’s patient selection
In this issue of Blood, Lamy et al present the results of the LYSA/GOELAMS trial 02-03, where patients with limited-stage diffuse large B-cell lymphoma (DLBCL) received either 4 or 6 cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) based on risk stratifica...
Bewaard in:
| Gepubliceerd in: | Blood |
|---|---|
| Hoofdauteur: | |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
American Society of Hematology
2018
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5757692/ https://ncbi.nlm.nih.gov/pubmed/29326347 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-11-813915 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|